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Abstract 
Mitochondria possess a central role in several cellular metabolic pathways, maintenance of 
calcium homeostasis, production of reactive oxygen species (ROS) and in the regulation of 
various cell death modalities. A majority of cancers demonstrate aberrations in mitochondrial 
functions, which were shown to contribute to tumourigenesis. In addition, many mechanisms of 
chemotherapy-resistance are located upstream of the mitochondria in cell death pathways. Thus, 
destabilization of mitochondria and permeabilization of the outer mitochondrial membrane 
(OMM), a point of no return in apoptosis induction, represent promising strategies for anticancer 
therapy. One major aim of this thesis was to identify therapeutic approaches to overcome 
resistance of cancer cells to conventional chemotherapeutic drugs. We could show in Paper I 
that chemotherapy resistance mechanisms in cancers, mediated by various oncogenic 
signalling/mutations, could be overcome by targeting Complex II of the mitochondrial respiratory 
chain. Treatment of Neuroblastoma (NB) cells with α-tocopheryl succinate (α-TOS), a redox-
silent analogue of vitamin-E, which was shown to target Complex II, mediate ROS-production 
and an increase of cytosolic calcium levels, could induce apoptosis in cancers cells irrespective 
of their MycN or p53 status. We propose that this is based on the ability of α-TOS to induce both 
mechanisms of OMM permeabilization, in a Bax/Bak-dependent manner, as well as calcium-
dependent induction of mitochondrial permeability transition (MPT).  
In Paper II and III we investigated the possibility of sensitizing cancer cells to conventional 
anticancer drugs in a co-treatment setting with compounds targeting Complex II. In case of α-
TOS (Paper II), the obtained results revealed contrasting effects for the chemotherapeutic drugs 
etoposide and cisplatin. In case of etoposide, α-TOS was able to sensitize cancer cells in a dose-
dependent manner. Whereas strikingly, in case of cisplatin, low concentration of α-TOS protected 
cells from cisplatin-induced toxicity. We demonstrated that the succinate moiety of α-TOS is 
mediating this protective effect via stimulation of Complex II activity. However, when Complex II 
was inhibited using thenoyltrifluoroacetone (TTFA) (Paper III), a specific inhibitor of the 
ubiquinone binding site of Complex II, cells could be sensitized to both, etoposide- and cisplatin-
induced cytotoxicity. This chemosensitizing effect was shown to rely on Complex II-mediated 
ROS-production.  
For the study that was concluded in Paper IV, a different approach was utilized. Citrate, a 
substrate of the tricarboxylic acid cycle, was shown to induce cytotoxicity in cells. The underlying 
mechanism was speculated to be based on citrate’s inhibitory effect on several crucial glycolytic 
enzymes and its ability to chelate calcium. We could demonstrate that although these features 
contribute, the main cause of cell death induced by citrate is the activation of initiator caspases. 
The underlying mechanism was proposed to be the kosmotropic property of citrate.  
In summary, the findings of this PhD thesis clearly underline the potency of exploiting 
mitochondria for anticancer therapy. Particularly Complex II plays an intriguing role in the 
sensitivity towards chemotherapy and represents an attractive target that should be further 
explored in future projects. In addition, new roles of well-known mitochondrial substrates were 
revealed. 
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